Novartis' Hantson to lead Baxter's international business

Share this article:
Novartis North America pharma chief Ludwig Hantson, PhD has joined specialty biopharma Baxter International as head of international operations.

Hantson, whose departure from Novartis was confirmed yesterday, starts at Baxter as corporate VP and president, international on May 3. Based in Deerfield, IL, Baxter makes treatments for hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.

Hantson, 47, joined Novartis from Janssen Pharmaceutica in 2001, and headed the company's US specialty pharmaceuticals business and its European pharmaceuticals operations before being named CEO, pharma for North America in 2008.  

“Geographic expansion continues to be a key growth driver for Baxter,” said Baxter chairman and CEO Robert Parkinson, Jr. in a statement. “Our global presence and the strength of our local and regional organizations position us to meet the ever-increasing demand for healthcare worldwide, particularly for the medically necessary products that we provide. Ludwig brings significant international and scientific knowledge and expertise to Baxter, and he will be a tremendous asset to the company in his new role leading our international business.”

Novartis said yesterday a replacement for Hantson would be announced “shortly.” The Swiss drug giant confirmed other significant changes to its US business following an In Vivo report. The company will establish four new US business units focused on primary care, multiple sclerosis, psychiatry/neuroscience and respiratory/transplant/infectious disease while consolidating its five regional offices in primary care sales and marketing to four, eliminating 383 mostly headquarters-based posts in the process but adding reps on its MS sales force as it seeks approval for Gilenia (fingolimod).
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...